Inflammation-mediated diabetes-liver disease cross-organ crosstalk: From molecular mechanisms to precision therapeutic strategies
- 24 June 2026
- journal article
- review article
- Published by Elsevier in Life Sciences
- Vol. 402, 124534
Abstract
No abstract availableKeywords
Funding Information
- Hebei Provincial Department of Science and Technology
- Department of Education of Hebei Province
- Tangshan Science and Technology Bureau
- National Natural Science Foundation of China
This publication has 81 references indexed in Scilit:
- Intestinal barrier in chronic gut and liver diseases: Pathogenesis and therapeutic targetsActa Pharmaceutica Sinica B, 2025
- From omics to AI —mapping the pathogenic pathways in type 2 diabetesFEBS Letters, 2025
- The pathophysiological link between type 1 diabetes and MASLD: insights into insulin resistance and liver dysfunctionJournal of Endocrinological Investigation, 2025
- Targeting the NLRP3 inflammasome–IL-1β pathway in type 2 diabetes and obesityDiabetologia, 2024
- Nanoformulations for the diagnosis and treatment of metabolic dysfunction-associated steatohepatitisActa Biomaterialia, 2024
- Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease populationDiabetes Research and Clinical Practice, 2024
- METTL3 Modulates TXNIP Expression to Affect the Activation of NLRP3 Inflammasome in Hepatic Cells Under Oxygen–Glucose Deprivation/Reperfusion InjuryInflammation, 2024
- Steatotic liver disease, MASLD and risk of chronic kidney diseaseDiabetes & Metabolism, 2023
- Mechanisms of interorgan crosstalk in health and diseaseFEBS Letters, 2022
- Exosomes from adipose-derived mesenchymal stem cells ameliorate cardiac damage after myocardial infarction by activating S1P/SK1/S1PR1 signaling and promoting macrophage M2 polarizationThe International Journal of Biochemistry & Cell Biology, 2019